{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:01:17Z","timestamp":1762916477308,"version":"3.45.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021852","name":"Centre Hospitalier Universitaire de Poitiers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022108","name":"Universit\u00e9 de Poitiers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ijpx.2023.100178","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T19:49:10Z","timestamp":1678564150000},"page":"100178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["PK-PD Evaluation of Inhaled Microparticles loaded with Ciprofloxacin-Copper complex in a Rat Model of Chronic Pseudomonas aeruginosa Lung Infection."],"prefix":"10.1016","volume":"5","author":[{"given":"Frederic","family":"Tewes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Lamarche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpx.2023.100178_bb0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s004080000031","article-title":"Virulence factors from Pseudomonas aeruginosa increase lung epithelial permeability","volume":"178","author":"Azghani","year":"2000","journal-title":"Lung"},{"key":"10.1016\/j.ijpx.2023.100178_bb0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ppul.21011","article-title":"Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients","volume":"44","author":"Bjarnsholt","year":"2009","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ijpx.2023.100178_bb0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/431516","article-title":"Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model","volume":"192","author":"Bragonzi","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpx.2023.100178_bb0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/pharmaceutics12040387","article-title":"Control of the lung residence time of highly permeable molecules after nebulization: example of the fluoroquinolones","volume":"12","author":"Brillault","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2023.100178_bb0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejps.2016.11.011","article-title":"In vitro biopharmaceutical evaluation of ciprofloxacin\/metal cation complexes for pulmonary administration","volume":"97","author":"Brillault","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2023.100178_bb0030","first-page":"53","article-title":"Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans","volume":"75","author":"Cipolla","year":"2014","journal-title":"Adv. Drug Deliv. Rev. Improv. Effic. Inhaled Drugs Sev. Lung Diseas.: Emerg. Pulmon. Deliv. Strateg."},{"key":"10.1016\/j.ijpx.2023.100178_bb0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of liposomal ciprofloxacin to treat lung infections","volume":"8","author":"Cipolla","year":"2016","journal-title":"Pharmaceutics"},{"year":"2011","series-title":"Treatment of bacterial diseases of the respiratory organs","author":"Endermann","key":"10.1016\/j.ijpx.2023.100178_bb0040"},{"key":"10.1016\/j.ijpx.2023.100178_bb0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejps.2016.08.024","article-title":"Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres","volume":"93","author":"Gaspar","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2023.100178_bb0050","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(10)60088-4","article-title":"Pharmacokinetics (PK) of aerosol MP-376 (aeroquin; levofloxacin inhalation solution) in CF patients","volume":"9","author":"Geller","year":"2010","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ijpx.2023.100178_bb0055","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/AAC.02818-14","article-title":"Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin","volume":"58","author":"Gontijo","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"year":"2014","series-title":"Aerosol Fluoroquinolone Formulations for Improved Pharmacokinetics","author":"Griffith","key":"10.1016\/j.ijpx.2023.100178_bb0060"},{"key":"10.1016\/j.ijpx.2023.100178_bb0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jcf.2010.12.007","article-title":"Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin","volume":"10","author":"Growcott","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ijpx.2023.100178_bb0070","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejpb.2017.04.032","article-title":"Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections","volume":"117","author":"G\u00fcnday T\u00fcreli","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2023.100178_bb0075","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1258\/la.2007.06014e","article-title":"Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies","volume":"42","author":"Kukavica-Ibrulj","year":"2008","journal-title":"Lab. Anim."},{"key":"10.1016\/j.ijpx.2023.100178_bb0080","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2017.12.021","article-title":"New aerosol formulation to control ciprofloxacin pulmonary concentration","volume":"271","author":"Lamy","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2023.100178_bb0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.34154\/2019-EJPR.01(01).pp-02-11\/euraass","article-title":"Use of leucine to improve aerodynamic properties of ciprofloxacin-loaded maltose microparticles for inhalation","volume":"1","author":"Lamy","year":"2019","journal-title":"Eur. J. Pharmaceut. Res."},{"key":"10.1016\/j.ijpx.2023.100178_bb0090","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1128\/AAC.00411-10","article-title":"Aerosol Therapy with Colistin Methanesulfonate: a Biopharmaceutical issue Illustrated in Rats","volume":"54","author":"Marchand","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2023.100178_bb0095","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/AAC.05360-11","article-title":"Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic\/pharmacodynamic target","volume":"56","author":"Martinez","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2023.100178_bb0100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pupt.2018.03.005","article-title":"Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug\u2013device combination","volume":"50","author":"McShane","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ijpx.2023.100178_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105028","article-title":"Sustained-release microparticle dry powders of chloramphenicol palmitate or thiamphenicol palmitate prodrugs for lung delivery as aerosols","volume":"138","author":"Nurbaeti","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2023.100178_bb0110","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1128\/AAC.00306-13","article-title":"Ciprofloxacin is actively Transported across bronchial lung epithelial cells using a Calu-3 air interface cell model","volume":"57","author":"Ong","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2023.100178_bb0115","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.clinthera.2016.06.015","article-title":"Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing","volume":"38","author":"Onufrak","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijpx.2023.100178_bb0120","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpx.2023.100178_bb0125","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1128\/AAC.31.11.1809","article-title":"Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats","volume":"31","author":"Roosendaal","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2023.100178_bb0130","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1128\/AAC.00268-09","article-title":"Efficacy of Aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa","volume":"53","author":"Sabet","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2023.100178_bb0135","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ijpx.2023.100178_bb0140","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijpx.2023.100178_bb0145","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.clinthera.2013.08.003","article-title":"Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study","volume":"35","author":"Stass","year":"2013","journal-title":"Clin. Ther."},{"year":"2013","series-title":"Aerosolized Fluoroquinolones and Uses Thereof","author":"Surber","key":"10.1016\/j.ijpx.2023.100178_bb0150"},{"key":"10.1016\/j.ijpx.2023.100178_bb0155","unstructured":"Surber, M.W., Bostian, K.A., Griffith, D.C., Dudley, M.N., Rodny, O., 2017. Aerosol fluoroquinolone formulations for improved pharmacokinetics. MX345158B. patent EP2344129A1."},{"key":"10.1016\/j.ijpx.2023.100178_bb0160","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1021\/acs.molpharmaceut.5b00543","article-title":"Ciprofloxacin-loaded inorganic\u2013organic composite microparticles to treat bacterial lung infection","volume":"13","author":"Tewes","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2023.100178_bb0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1208\/s12249-019-1417-9","article-title":"Efficacy of Ciprofloxacin and its copper complex against Pseudomonas aeruginosaBiofilms","volume":"20","author":"Tewes","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2023.100178_bb0170","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejpb.2020.05.014","article-title":"In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa","volume":"152","author":"Tewes","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2023.100178_bb0175","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/09031936.00090314","article-title":"Inhaled antibiotics: dry or wet?","volume":"44","author":"Tiddens","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijpx.2023.100178_bb0180","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02553-16","article-title":"Population pharmacokinetic modeling as a tool to characterize the decrease in ciprofloxacin free interstitial levels caused by pseudomonas aeruginosa biofilm lung infection in wistar rats","volume":"61","author":"Torres","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2023.100178_bb0185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejpb.2019.08.006","article-title":"In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: are agar and calcium-alginate beads interchangeable?","volume":"143","author":"Torres","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2023.100178_bb0190","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jcf.2010.03.001","article-title":"Alveolar inflammation in cystic fibrosis","volume":"9","author":"Ulrich","year":"2010","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ijpx.2023.100178_bb0195","article-title":"Pulmonary delivery of a fluoroquinolone","author":"Weers","year":"2009","journal-title":"CA2724009A1. patent US20090992371"},{"key":"10.1016\/j.ijpx.2023.100178_bb0200","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/CMR.00101-15","article-title":"Inhaled antibiotics for gram-negative respiratory infections","volume":"29","author":"Wenzler","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijpx.2023.100178_bb0205","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4155\/tde.11.19","article-title":"Flip-flop pharmacokinetics \u2013 delivering a reversal of disposition: challenges and opportunities during drug development","volume":"2","author":"Y\u00e1\u00f1ez","year":"2011","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ijpx.2023.100178_bb0210","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/AAC.01705-13","article-title":"Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration","volume":"58","author":"Yapa","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2023.100178_bb0215","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2014.10.022","article-title":"Inhaled formulations and pulmonary drug delivery systems for respiratory infections","volume":"85","author":"Zhou","year":"2015","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156723000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156723000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:39:29Z","timestamp":1762915169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156723000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":43,"alternative-id":["S2590156723000221"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2023.100178","relation":{},"ISSN":["2590-1567"],"issn-type":[{"type":"print","value":"2590-1567"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PK-PD Evaluation of Inhaled Microparticles loaded with Ciprofloxacin-Copper complex in a Rat Model of Chronic Pseudomonas aeruginosa Lung Infection.","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2023.100178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100178"}}